EBITDA Margin % is calculated as EBITDA divided by its Revenue. UroGen Pharma's EBITDA for the
three
months ended in Mar. 2026 was €-20.3 Mil. UroGen Pharma's Revenue for the
three
months ended in Mar. 2026 was €44.1 Mil. Therefore, UroGen Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -46.13%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
UroGen Pharma EBITDA Margin % Related Terms
UroGen Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs OCS, SEPN, AVBP: EBITDA Margin % Comparison
For the Biotechnology subindustry, UroGen Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a EBITDA Margin % of -46.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #490 out of 944 companies in the Biotechnology industry, placing it in the top 51.9%.
Is UroGen Pharma's EBITDA Margin % too high?
UroGen Pharma's current EBITDA Margin % is -46.13%. Based on the distribution chart, UroGen Pharma ranks #490 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's EBITDA Margin % compare to OCS and SEPN?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #490 out of 944 companies for EBITDA Margin %. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current EBITDA Margin % is -46.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current EBITDA Margin % is -46.13%. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current EBITDA Margin % is -46.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
EBITDA Margin %: -46.13%
GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score
Get the complete analysis for FRA:UR8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
